HOME >> BIOLOGY >> NEWS
OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer

te, and reinforces our position as the leader in this emerging area of cancer therapy."

"The pre-clinical and early clinical experience of CA4P makes the compound extremely well-suited for study in Phase II," said the trial's lead investigator, Scot C. Remick, M.D., Associate Professor of Medicine and International Health at University Hospitals of Cleveland and Case Western Reserve University School of Medicine. "Based on our Phase I experience, we are very pleased to continue development of this compound for the treatment of ATC. This clinical trial offers a unique opportunity to investigate a novel anti-tumor treatment, and to potentially establish CA4P as a new therapy."

In addition to the trial announced today, a Phase Ib trial of CA4P is underway at the University of Pennsylvania's Presbyterian Medical Center, where researchers are studying the VTA in combination with a chemotherapy drug called Carboplatin.

CA4P attacks the vascular structure of solid tumors and other diseases characterized by the formation of aberrant blood vessels. The compound triggers a change in the shape of endothelial cells lining a tumor's blood vessels. This in turn blocks the flow of blood to the tumor, depriving it of oxygen and nutrients. The compound is a synthetic form of CA4, a natural substance found in the bark of the South African willow tree known as combretum caffrum. CA4 was identified and isolated in 1987 by Professor G. Robert Pettit, director of the Cancer Research Institute at Arizona State University.

"Our Phase II study represents an opportunity to assess the preliminary efficacy of CA4P in a specific indication," said Dai Chaplin, Ph.D., OXiGENE's chief scientific officer. "This is particularly exciting because our Phase I study resulted in a complete pathological response in a patient with the identical disease."


'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
23-Dec-2002


Page: 1 2

Related biology news :

1. OXiGENE launches significant expansion of its R&D program in ophthalmology
2. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
3. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
4. OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
5. Secretary of Energy announces seven E.O. Lawrence Award Winners
6. Popular Science announces Third Annual Brilliant 10
7. The American Phytopathological Society announces 2004 awards
8. NSF announces six FIBR awards to tackle some of biologys most challenging questions
9. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
10. JGI announces community sequencing program portfolio
11. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics

Post Your Comments:
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
(Date:4/17/2015)... Global Stem Cells Group ... Summit 2015 April 27 - 29, 2015 in Boston. ... all areas of stem cell research including applications, biology, ... regenerative medicine. , The conference will address recent ... translational research in stem cell therapies, regenerative medicine, tissue ...
(Date:4/17/2015)... 17, 2015 BellBrook Labs announced ... support for the powerful Orthogonal Pooled Screening (OPS) ... Center at the Lankenau Institute for Medical Research ... to measurably improve successful drug discovery outcomes using ... rare, drug-like libraries available nowhere else, coupled to ...
(Date:4/16/2015)... and OSAKA, Japan , April ... Application (CiRA) of Kyoto University and Takeda Pharmaceutical ... work together to develop clinical applications of induced ... failure, diabetes mellitus, neurological disorders and cancer immunotherapy. ... (T-CiRA) is designed to expedite multiple research projects ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
Breaking Biology Technology:Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
Cached News: